The AstraZeneca PLC ADR AZN slid 2.83% to $64.87 Thursday, on what proved to be an all-around poor trading session for the ...

AstraZeneca to buy EsoBiotec for up to $1 billion Deal aims to enhance cancer cell therapy capabilities AstraZeneca secures global rights to Alteogen's ALT-B4 enzyme AstraZeneca shares up almost ...

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. The deal will see AstraZeneca scoop up all ...

AstraZeneca’s (AZN) Imfinzi in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy has been approved in the ...

Barclays analyst Emily Field maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £140.00. The company’s shares closed yesterday at p11,904.00.

EsoBiotec SA has entered into a definitive agreement to be acquired by AstraZeneca (NASDAQ:AZN) for up to $1 billion, on a cash and debt-free basis, it said on Monday. The deal includes an initial ...

Eneboparatide hits primary endpoint in AstraZeneca’s Phase 3 trial for chronic hypoparathyroidism, showing significant efficacy at 24 weeks. The EU approved AstraZeneca’s Imfinzi for limited ...

By Chandini Monnappa (Reuters) -Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, seeking to accelerate the development of ...

AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. The ...

AstraZeneca bought Belgian biotech company EsoBiotec in a deal valued at up to $1 billion, to expand its cell-therapy portfolio. The British pharma company said Monday that it will pay $425 ...

AstraZeneca has announced two separate deals that will see the company acquire EsoBiotec for up to $1 billion as well as a licensing deal with Alteogen that will expand its work in oncology and cell ...

A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps eneboparatide on track to come to market, but the lack of numbers in the ...